<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812442037</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812442037</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Judd</surname><given-names>Nancy P.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812442037">1</xref>
<xref ref-type="fn" rid="fn1-0194599812442037">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Allen</surname><given-names>Clint T.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812442037">1</xref>
<xref ref-type="fn" rid="fn1-0194599812442037">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Winkler</surname><given-names>Ashley E.</given-names></name>
<xref ref-type="aff" rid="aff1-0194599812442037">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Uppaluri</surname><given-names>Ravindra</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812442037">1</xref>
<xref ref-type="aff" rid="aff2-0194599812442037">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599812442037"><label>1</label>Department of Otolaryngology, Washington University School of Medicine, St Louis, Missouri, USA</aff>
<aff id="aff2-0194599812442037"><label>2</label>John Cochran VA Medical Center, Washington University School of Medicine, St Louis, Missouri, USA</aff>
<author-notes>
<corresp id="corresp1-0194599812442037">Ravindra Uppaluri, MD, PhD, Washington University School of Medicine, Department of Otolaryngology, Box 8115, 660 South Euclid Ave, St Louis, MO 63110, USA Email: <email>uppalurr@wustl.edu</email>
</corresp>
<fn fn-type="other" id="fn1-0194599812442037">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>147</volume>
<issue>3</issue>
<fpage>493</fpage>
<lpage>500</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>8</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>2</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0194599812442037">
<title>Objective</title>
<p>To perform a comparative analysis of infiltrating immune cells in a newly developed C57BL/6 background syngeneic transplantable mouse oral cancer (MOC) model.</p>
</sec>
<sec id="section2-0194599812442037">
<title>Study Design/Setting</title>
<p>Scientific study in an academic medical center.</p>
</sec>
<sec id="section3-0194599812442037">
<title>Methods</title>
<p>Use of carcinogen-induced tumorigenesis, tissue culture, cell line transplantation, and flow cytometric analysis techniques.</p>
</sec>
<sec id="section4-0194599812442037">
<title>Results</title>
<p>Previously, the authors established a series of cell line models that displayed dichotomous growth phenotypes when transplanted into immunocompetent mice. They now show that the indolent growth pattern of the MOC1-generated tumors is associated with increased baseline and inducible major histocompatibility complex class I expression and increased CD8<sup>+</sup> T-cell infiltration into the tumor microenvironment. Conversely, the aggressive and metastatic pattern of MOC2-generated tumors has decreased basal and inducible class I expression and is associated with FOXP3<sup>+</sup>CD4<sup>+</sup> regulatory T-cell infiltration. Delayed primary tumor growth after targeted monoclonal antibody therapy of these FOXP3<sup>+</sup> regulatory cells further suggests that these immune cells contribute to the aggressive phenotype of MOC2.</p>
</sec>
<sec id="section5-0194599812442037">
<title>Conclusion</title>
<p>These data validate that key infiltrating immune cells identified here parallel findings in human head and neck cancer, making this newly developed syngeneic model a critical platform for the continued dissection of tumor-host interactions in head and neck cancer.</p>
</sec>
</abstract>
<kwd-group>
<kwd>syngeneic model</kwd>
<kwd>oral cancer</kwd>
<kwd>tumor infiltrating lymphocytes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Despite characterization of intracellular progrowth and prosurvival signaling pathways that drive head and neck squamous cell carcinoma (HNSCC) oncogenesis, meaningful change in patient outcomes using this knowledge has not occurred.<sup><xref ref-type="bibr" rid="bibr1-0194599812442037">1</xref></sup> Patients with carcinogen-associated HNSCC demonstrate high locoregional failure and distant metastasis rates and poor disease-specific survival despite aggressive treatments.<sup><xref ref-type="bibr" rid="bibr2-0194599812442037">2</xref></sup> Conversely, patients with human papillomavirus (HPV)–associated oropharyngeal cancer have high rates of cure. A natural host antitumor response to strong viral antigens may contribute to these improved outcomes.<sup><xref ref-type="bibr" rid="bibr3-0194599812442037">3</xref></sup> Based on this concept and other lines of evidence, there is growing interest in enhancing natural antitumor responses to augment current approaches in the treatment of carcinogen-associated HNSCC.</p>
<p>Early evidence implicating the presence of a productive host antitumor immune response was derived from studies in mice.<sup><xref ref-type="bibr" rid="bibr4-0194599812442037">4</xref></sup> Evidence of such responses in humans comes in part from elevated rates of malignancy in immunocompromised patients.<sup><xref ref-type="bibr" rid="bibr5-0194599812442037">5</xref></sup> In patients with HNSCC, tumor infiltration of cells involved in and a gene expression profile indicative of an adaptive immune response predicted improved outcomes.<sup><xref ref-type="bibr" rid="bibr6-0194599812442037">6</xref><xref ref-type="bibr" rid="bibr7-0194599812442037"/><xref ref-type="bibr" rid="bibr8-0194599812442037"/><xref ref-type="bibr" rid="bibr9-0194599812442037"/>-<xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref></sup> In contrast, recent evidence has supported a protumorigenic role for the immune system involving cells that suppress cellular immunity both locally and systemically in patients with HNSCC.<sup><xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref></sup></p>
<p>One major void in the preclinical study of immune responses to HNSCC is the lack of syngeneic transplantable models in mouse strains.<sup><xref ref-type="bibr" rid="bibr9-0194599812442037">9</xref></sup> The majority of transplantable HNSCC models to date are xenograft models, which recapitulate local growth and metastasis but require immunodeficient hosts that lack components of adaptive immunity.<sup><xref ref-type="bibr" rid="bibr11-0194599812442037">11</xref>,<xref ref-type="bibr" rid="bibr12-0194599812442037">12</xref></sup> To address this deficiency, we generated carcinogen-induced oral cancer cell lines that are transplantable into widely used immunocompetent C57BL/6 mice.<sup><xref ref-type="bibr" rid="bibr13-0194599812442037">13</xref>,<xref ref-type="bibr" rid="bibr14-0194599812442037">14</xref></sup> With this syngeneic oral cancer model, we are able to study components of the host immune response to transplanted cancer cells.</p>
<p>Previously, we established C57BL/6 mouse oral cancer (MOC) lines that demonstrate either indolent or aggressive in vivo growth phenotypes. We hypothesized that differences in these growth phenotypes are influenced by immune cell infiltration. To address this hypothesis, we compared MOC line tumor growth in immunocompetent (wild-type, WT) and immunodeficient (RAG2<sup>–/–</sup>) mice. We compared the immunogenicity of the aggressive and indolent MOC lines by analyzing levels of cell surface major histocompatibility complex (MHC) class I expression. We also characterized immune cells infiltrating into the tumor microenvironment, regional lymph nodes, and spleens of mice transplanted with both indolent and aggressive MOC cells. Furthermore, we characterized the functionality of a subset of tumor-infiltrating immune cells via antibody-mediated knockdown and subsequent tumor growth analysis.</p>
<sec id="section6-0194599812442037" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section7-0194599812442037">
<title>Animals</title>
<p>C57BL/6 and RAG2<sup>–/–</sup> mice were obtained from Taconic (Hudson, New York). Animal Studies and Research Ethics Committees of Washington University in St Louis approved all animal studies and experimental protocols.</p>
</sec>
<sec id="section8-0194599812442037">
<title>Antibodies</title>
<p>Anti-CD45, -CD45.2, -CD4, -CD8, -GR1, -CD11b, -F4/80, -Rat IgG2B, -Class I-K<sup>b</sup>, -Class I-K<sup>d</sup>, and -Class I-D<sup>b</sup> were from Biolegend (San Diego, California). Intracellular APC-FoxP3 (eBioscience, San Diego, California) was used according to the manufacturer’s recommendations. T regulatory cell (Treg) depletion was performed as previously described.<sup><xref ref-type="bibr" rid="bibr15-0194599812442037">15</xref></sup></p>
</sec>
<sec id="section9-0194599812442037">
<title>Cell Lines</title>
<p>Using repeated carcinogen exposure to induce transformation, we generated syngeneic C57BL/6 MOC cell lines as described previously.<sup><xref ref-type="bibr" rid="bibr13-0194599812442037">13</xref></sup> Cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM)/F12 at a 2:1 mixture with 5% fetal calf serum (FCS; Fisher Scientific, Houston, Texas), 1% penicillin/streptomycin, 1% amphotericin, 5 ng/mL epidermal growth factor (EGF; Millipore, Billerica, Massachusetts), 400 ng/mL hydrocortisone, and 5 mg/mL insulin (Sigma Chemical, St Louis, Missouri).</p>
</sec>
<sec id="section10-0194599812442037">
<title>Flow Cytometry</title>
<p>Transplanted flank tumors were harvested and digested to single-cell suspension with Collagenase Type IA (1 mg/mL; Sigma Chemical). Draining lymph nodes and spleen were harvested into single-cell suspensions by crushing between frosted glass slides. Splenocytes were treated with Red Blood Cell Lysis Buffer (Sigma Chemical). Cells were washed twice and blocked with rat antimouse CD16/CD32 (BD Biosciences, San Jose, California) for 15 minutes. Staining was done with appropriate antibodies at 4°C for 30 minutes. Cells were further washed and flow cytometry was performed using a FACSCalibur (BD Biosciences). Data were analyzed using FloJo software (Tree Star, Ashland, Oregon).</p>
</sec>
<sec id="section11-0194599812442037">
<title>MHC Class I Expression</title>
<p>Cultured MOC1 and MOC2 cells were treated with vehicle control or interferon-γ; (1000 units) for 72 hours. Cells were harvested with 0.25% Trypsin (Hyclone, Logan, Utah), washed twice, stained, and analyzed as above.</p>
</sec>
<sec id="section12-0194599812442037">
<title>Tumor Transplantation</title>
<p>The MOC cells were harvested, washed twice in Dulbecco’s phosphate-buffered saline (D-PBS; Fisher, Houston, Texas), resuspended at appropriate concentration, and injected into the right subcutaneous flanks of WT C57BL/6 and RAG2<sup>–/–</sup> mice. Mice were monitored for tumor growth biweekly, and tumor size was recorded as the average of the 2 largest diameters. Tumors, draining lymph nodes, and spleens were harvested for fluorescence-activated cell sorting (FACS) evaluation and hematoxylin and eosin (H&amp;E) staining.</p>
</sec>
<sec id="section13-0194599812442037">
<title>Statistics</title>
<p>Tumor growth was analyzed by single-day comparison analysis using the Mann-Whitney <italic>U</italic> test (nonparametric equivalent of independent samples <italic>t</italic> test). All other analyses used the independent samples <italic>t</italic> test.</p>
</sec>
</sec>
<sec id="section14-0194599812442037" sec-type="results">
<title>Results</title>
<sec id="section15-0194599812442037">
<title>MOC Cell Lines Have Different Growth Phenotypes In Vivo</title>
<p>As representative models for the 2 growth phenotypes, we compared MOC1, which is less aggressive, and MOC2, which is a highly invasive cell line that spontaneously metastasizes to draining lymph nodes following flank transplantation. Previous work demonstrated that both MOC1 and MOC2 formed tumors when 1 × 10<sup>6</sup> cells were transplanted into the flanks of WT mice and that similar growth phenotypes were observed between flank and orthotopically transplanted tumors.<sup><xref ref-type="bibr" rid="bibr13-0194599812442037">13</xref></sup> We found that the kinetics of tumor growth was more rapid at a 10-fold decreased inoculum of 1 × 10<sup>5</sup> MOC2 cells/mouse when compared with MOC1 at 1 × 10<sup>6</sup> cells/mouse (<xref ref-type="fig" rid="fig1-0194599812442037"><bold>Figure 1A</bold></xref>), demonstrating the more aggressive phenotype of MOC2 cells. When parallel transplantation of these same cell lines into flanks of immunodeficient RAG2<sup>–/–</sup> mice was performed, MOC2 produced tumors that also grew faster than MOC1 (<xref ref-type="fig" rid="fig1-0194599812442037"><bold>Figure 1A</bold></xref>). Interestingly, whereas there was no difference in MOC2 tumor growth between RAG2<sup>–/–</sup> and WT mice, tumors formed after MOC1 cell transplantation grew slower in WT compared with RAG2<sup>–/–</sup> mice (<xref ref-type="fig" rid="fig1-0194599812442037"><bold>Figure 1A</bold></xref>).</p>
<fig id="fig1-0194599812442037" position="float">
<label>Figure 1.</label>
<caption>
<p>Growth rates and class I expression of mouse oral cancer (MOC) lines. (A) Growth curves of transplanted MOC lines. (B) Class I K<sup>b</sup> expression at baseline and after interferon (IFN)–γ stimulation. (C) Baseline expression of K<sup>b</sup> on MOC lines. (D) Induced expression of K<sup>b</sup> on MOC lines.</p>
</caption>
<graphic xlink:href="10.1177_0194599812442037-fig1.tif"/>
</fig>
</sec>
<sec id="section16-0194599812442037">
<title>Higher MHC Class I Expression in MOC1 Compared with MOC2</title>
<p>Having observed growth rate differences between MOC1 and MOC2 tumors in WT mice and a decreased growth rate of MOC1 in RAG2<sup>–/–</sup> mice compared with MOC2 cells, we next evaluated the cell surface MHC class I expression of the 2 cell lines as a possible explanation. Comparison of constitutive H2-K<sup>b</sup> showed that MOC1 had a 12-fold increased expression relative to MOC2 (<xref ref-type="fig" rid="fig1-0194599812442037"><bold>Figure 1B</bold></xref>-<xref ref-type="fig" rid="fig1-0194599812442037"><bold>C</bold></xref>). In addition, MOC1 also had slightly elevated levels of constitutive H2-D<sup>b</sup> expression (data not shown). To assess induction of class I components, cells were treated with IFN-γ (1000 units) for 72 hours. Fluorescence-activated cell sorting analysis demonstrated that MOC1 cells show a 2.5-fold increase in inducible H2-K<sup>b</sup> (<xref ref-type="fig" rid="fig1-0194599812442037"><bold>Figure 1B</bold></xref>-<xref ref-type="fig" rid="fig1-0194599812442037"><bold>D</bold></xref>) and a 2-fold increase in inducible H2-D<sup>b</sup> expression (data not shown) compared with MOC2 cells. Thus, differences in constitutive and inducible MHC class I component expression between MOC1 and MOC2 cells correlated with growth phenotypes.</p>
</sec>
<sec id="section17-0194599812442037">
<title>Tumor-Infiltrating CD11b<sup>+</sup>/Gr1<sup>+</sup> Cells</title>
<p>We next analyzed tumor-infiltrating immune cells. When MOC1- and MOC2-generated tumors reached a diameter of 8 mm, tumors, draining lymph nodes, and spleens were harvested and infiltrating immune cells were evaluated via flow cytometry. Non-tumor-bearing spleens and lymph nodes served as controls. There was an 8- to 9-fold increase in CD11b<sup>+</sup>/Gr1<sup>+</sup> cells present in the spleen of tumor-bearing mice compared with non-tumor-bearing controls (<xref ref-type="fig" rid="fig2-0194599812442037"><bold>Figure 2A</bold></xref>). However, there were no significant differences in CD11b<sup>+</sup>/Gr1<sup>+</sup> cells between the spleens of MOC1- and MOC2-transplanted mice (statistical data not shown). Significant levels of CD11b<sup>+</sup>/Gr1<sup>+</sup> cells were present in the tumor microenvironment, and no significant differences in infiltrating CD11b<sup>+</sup>/Gr1<sup>+</sup> cells between tumors generated from MOC1 and MOC2 transplantation were observed (<xref ref-type="fig" rid="fig2-0194599812442037"><bold>Figure 2B</bold></xref>).</p>
<fig id="fig2-0194599812442037" position="float">
<label>Figure 2.</label>
<caption>
<p>Expanded CD11b<sup>+</sup>/Gr1<sup>+</sup> cells in mouse oral cancer (MOC) lines. (A) Representative fluorescence-activated cell sorting (FACS) data from mouse spleens. (B) Representative data from MOC-generated tumors. (C) FACS data from regional lymph nodes. Hematoxylin and eosin–stained sections of tumor-draining lymph nodes. SCC, squamous cell carcinoma.</p>
</caption>
<graphic xlink:href="10.1177_0194599812442037-fig2.tif"/>
</fig>
</sec>
<sec id="section18-0194599812442037">
<title>Increased CD11b<sup>+</sup>/Gr1<sup>+</sup> Cell Infiltration in Metastatic Lymph Nodes</title>
<p>As previously described, MOC2-generated tumors spontaneously metastasize to draining lymph nodes, whereas MOC1-generated tumors do not demonstrate a metastatic phenotype.<sup><xref ref-type="bibr" rid="bibr13-0194599812442037">13</xref></sup> There was minimal CD11b<sup>+</sup>/Gr1<sup>+</sup> cell infiltration in draining lymph nodes of non-tumor-bearing mice and MOC1 tumor-bearing mice. However, increased infiltration or expansion of CD11b<sup>+</sup>/Gr1<sup>+</sup> cells was observed in lymph nodes containing metastatic disease from MOC2-generated flank tumors (<xref ref-type="fig" rid="fig2-0194599812442037"><bold>Figure 2B</bold></xref>). This CD11b<sup>+</sup>/Gr1<sup>+</sup> cell infiltrate was not correlated with primary tumor growth.</p>
</sec>
<sec id="section19-0194599812442037">
<title>Infiltrating CD11b<sup>+</sup>/Gr1<sup>–</sup> Cells Are F4/80<sup>+</sup></title>
<p>In the microenvironment of both MOC1 and MOC2 tumors, there was a large infiltration of CD11b<sup>+</sup>/Gr1<sup>–</sup> cells in addition to CD11b<sup>+</sup>/Gr1<sup>+</sup> cells (<xref ref-type="fig" rid="fig3-0194599812442037"><bold>Figure 3</bold></xref>). Flow cytometric analysis of this population showed that a significant portion of these cells was F4/80<sup>+</sup> (<xref ref-type="fig" rid="fig3-0194599812442037"><bold>Figure 3</bold></xref>). There was no significant difference in the tumor infiltration of CD11b<sup>+</sup>/Gr1<sup>–</sup>/F4/80<sup>+</sup> myeloid cells between MOC1- and MOC2-generated tumors (data not shown). Of note, the CD11b<sup>+</sup>/Gr1<sup>+</sup> infiltrating cells were F4/80<sup>–</sup>, establishing a population of cells used as a negative control. Interestingly, there were very few CD11b<sup>+</sup>/Gr1<sup>–</sup> cells present in either tumor-bearing or non-tumor-bearing draining lymph nodes in MOC1- or MOC2-transplanted mice (<xref ref-type="fig" rid="fig2-0194599812442037"><bold>Figure 2C</bold></xref>).</p>
<fig id="fig3-0194599812442037" position="float">
<label>Figure 3.</label>
<caption>
<p>CD11b<sup>+</sup>/Gr1<sup>–</sup> cells are F4/80<sup>+</sup>. (A) Representative fluorescence-activated cell sorting (FACS) plots of MOC1- or (B) MOC2-generated tumor microenvironments. CD11b<sup>+</sup>/Gr1<sup>+</sup> cells represent an F4/80 negative control.</p>
</caption>
<graphic xlink:href="10.1177_0194599812442037-fig3.tif"/>
</fig>
</sec>
<sec id="section20-0194599812442037">
<title>T-Cell Infiltration Corresponds to Tumor Growth Phenotype</title>
<p>Although no apparent correlation between myeloid cell infiltration and growth phenotype was seen, there were significant differences in CD4<sup>+</sup> and CD8<sup>+</sup> T-cell infiltration in the tumor microenvironment. MOC1-generated tumors demonstrated elevated CD8<sup>+</sup> T-cell infiltration (<xref ref-type="fig" rid="fig4-0194599812442037"><bold>Figure 4A</bold></xref>,<xref ref-type="fig" rid="fig4-0194599812442037"><bold>B</bold></xref>) and decreased CD4<sup>+</sup> T-cell infiltration into the tumor microenvironment (<xref ref-type="fig" rid="fig4-0194599812442037"><bold>Figure 4A</bold></xref>,<xref ref-type="fig" rid="fig4-0194599812442037"><bold>C</bold></xref>) compared with MOC2-generated tumors. In contrast, MOC2-generated tumors demonstrated elevated CD4<sup>+</sup> T-cell infiltration and decreased CD8<sup>+</sup> T-cell infiltration relative to MOC1-generated tumors. These data suggest that the less aggressive growth pattern of MOC1-generated tumors may be associated with an increased presence of CD8<sup>+</sup> T cells or, conversely, that elevated CD4<sup>+</sup> T-cell populations may contribute to the more aggressive growth pattern of MOC2-generated tumors.</p>
<fig id="fig4-0194599812442037" position="float">
<label>Figure 4.</label>
<caption>
<p>T -cell infiltration in the tumor microenvironment. (A) CD4<sup>+</sup> and CD8<sup>+</sup> cells in mouse oral cancer (MOC)–generated tumors. (B) Percentage live CD45<sup>+</sup>, CD8<sup>+</sup> cells in the tumor microenvironment (*<italic>P</italic> &lt; .05). (C) Percentage live CD45<sup>+</sup>, CD4<sup>+</sup> in the tumor microenvironment (***<italic>P</italic> &lt; .001).</p>
</caption>
<graphic xlink:href="10.1177_0194599812442037-fig4.tif"/>
</fig>
</sec>
<sec id="section21-0194599812442037">
<title>Tumor-Infiltrating CD4<sup>+</sup> T Cells Include Tregs That Contribute to the Aggressive Growth Phenotype of MOC2-Generated Tumors</title>
<p>CD4<sup>+</sup> T cells infiltrated the microenvironment of MOC2-generated tumors early and did not significantly fluctuate throughout growth (<xref ref-type="fig" rid="fig5-0194599812442037"><bold>Figure 5A</bold></xref>). Intracellular flow cytometric analysis for FoxP3, the critical transcription factor driving Treg development, was used to further characterize these CD4<sup>+</sup> T cells. A significant percentage of these cells were found to be FoxP3<sup>+</sup>, suggesting their functional role as Tregs (<xref ref-type="fig" rid="fig5-0194599812442037"><bold>Figure 5B</bold></xref> and data not shown). To assess the functional contribution of these cells, we used an established Treg-depleting regimen using an anti-CD25 (PC61) monoclonal antibody (mAb). Treatment with PC61 showed a modest but significant decrease in growth rate of MOC2-generated tumors compared with control antibody at days 11 and 14 after transplantation (<xref ref-type="fig" rid="fig5-0194599812442037"><bold>Figure 5C</bold></xref>). These data suggest that in our syngeneic model, Treg infiltration of the tumor microenvironment occurs early and at least in part contributes to the aggressive growth phenotype observed with MOC2-generated tumors.</p>
<fig id="fig5-0194599812442037" position="float">
<label>Figure 5.</label>
<caption>
<p>Depletion with anti-CD25 (PC61) attenuates mouse oral cancer 2 (MOC2) primary tumor growth. (A) CD4<sup>+</sup> T cells in the tumor microenvironment. (B) FoxP3 in the tumor microenvironment. (C) MOC2 tumors treated with HRPN or PC61. *<italic>P</italic> &lt; .05.</p>
</caption>
<graphic xlink:href="10.1177_0194599812442037-fig5.tif"/>
</fig>
</sec>
</sec>
<sec id="section22-0194599812442037" sec-type="discussion">
<title>Discussion</title>
<p>Here, we characterize infiltration of immune cells into the tumor microenvironment using a syngeneic, transplantable model of oral squamous cell carcinoma developed on a C57BL/6 genetic background.<sup><xref ref-type="bibr" rid="bibr13-0194599812442037">13</xref></sup> Our approach was to address the fidelity of this system in relation to human HNSCC and to identify key immune components that could serve as a basis for further investigation to delineate therapeutic targets. Similar to human HNSCC, we demonstrated that baseline immunogenicity and variable immune cell infiltration correlated with tumor aggressiveness.</p>
<p>The interaction between tumor cells and infiltrating immune and inflammatory cells is complex. Key mediators of this interaction have been correlated to clinical outcomes in HNSCC.<sup><xref ref-type="bibr" rid="bibr9-0194599812442037">9</xref></sup> Downregulation of cell surface MHC class I proteins, which are necessary for CD8<sup>+</sup> T-cell detection of tumor-associated antigenic material, is associated with tumor progression and poor survival in patients with HNSCC.<sup><xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref>,<xref ref-type="bibr" rid="bibr16-0194599812442037">16</xref><xref ref-type="bibr" rid="bibr17-0194599812442037"/>-<xref ref-type="bibr" rid="bibr18-0194599812442037">18</xref></sup> Here, we demonstrated significantly elevated basal and inducible expression of MHC class I molecules on cells from the more indolent MOC1-derived tumors. MOC1 cells with higher MHC class I expression demonstrated slower growth in immunocompetent WT mice compared with immunodeficient RAG2<sup>–/–</sup> mice, suggesting that 1 or more components of adaptive immunity that are lacking in RAG2<sup>–/–</sup> mice act to suppress tumor growth. Given our current understanding of MHC class I restriction of tumor antigen–specific CD8<sup>+</sup> cytotoxic T cells, we evaluated for and confirmed significantly elevated levels of CD8<sup>+</sup> T cells in MOC1-derived tumors compared with MOC2-derived tumors in WT mice.</p>
<p>This association between increased CD8<sup>+</sup> T cells and a more indolent growth pattern with MOC1-generated tumors parallels the improved outcomes associated with increased tumor-infiltrating CD8<sup>+</sup> T cells in patients with HNSCC. Patients whose primary and metastatic tumor deposits have higher levels of CD8<sup>+</sup> T cells demonstrated more favorable outcomes.<sup><xref ref-type="bibr" rid="bibr6-0194599812442037">6</xref>,<xref ref-type="bibr" rid="bibr7-0194599812442037">7</xref></sup> Yet, although CD8<sup>+</sup> T cells are crucial for antitumor immune responses, CD8<sup>+</sup> T-cell functional inhibition in the tumor microenvironment is the rule rather than the exception in patients with HNSCC.<sup><xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref></sup> These data have prompted investigation into the role of CD4<sup>+</sup> T-cell subsets in the HNSCC microenvironment.</p>
<p>Functionally unique from their CTL-inducing Th1 and humoral immunity-inducing Th2 counterparts, CD4<sup>+</sup>FOXP3<sup>+</sup> Tregs secrete immunosuppressive cytokines and inhibit antitumor CD8<sup>+</sup> T-cell responses.<sup><xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref>,<xref ref-type="bibr" rid="bibr19-0194599812442037">19</xref>,<xref ref-type="bibr" rid="bibr20-0194599812442037">20</xref></sup> Tregs play both a physiologic role in limiting autoimmunity and a pathologic role in many cancer types, including HNSCC.<sup><xref ref-type="bibr" rid="bibr21-0194599812442037">21</xref></sup> Although most studies have suggested that increased levels of tumor-associated or circulating Tregs are associated with poor survival,<sup><xref ref-type="bibr" rid="bibr22-0194599812442037">22</xref>-<xref ref-type="bibr" rid="bibr23-0194599812442037"/><xref ref-type="bibr" rid="bibr24-0194599812442037">24</xref></sup> others indicate improved prognosis in patients with elevated Treg levels.<sup><xref ref-type="bibr" rid="bibr25-0194599812442037">25</xref></sup> Here, we demonstrated elevated levels of CD4<sup>+</sup> T cells present in tumors generated from the more aggressive MOC2 cells and characterized a subset of these to be FOXP3<sup>+</sup>, suggesting their functional role as Tregs. Demonstrating the tumor-promoting role of Tregs in our model, we recorded growth inhibition of MOC2-generated tumors following antibody-mediated Treg depletion.</p>
<p>Interestingly, subpopulations of CD44<sup>+</sup> HNSCC tumor cells, shown to possess cancer stem cell properties and resistance to standard anticancer therapies,<sup><xref ref-type="bibr" rid="bibr26-0194599812442037">26</xref>,<xref ref-type="bibr" rid="bibr27-0194599812442037">27</xref></sup> more effectively induce immunosuppressive Treg responses in vitro.<sup><xref ref-type="bibr" rid="bibr27-0194599812442037">27</xref></sup> Our laboratory has previously reported that MOC2 cells, which generate tumors with elevated levels of infiltrating Tregs, also express high levels of CD44 compared with MOC1 cells,<sup><xref ref-type="bibr" rid="bibr13-0194599812442037">13</xref></sup> further demonstrating biologic differences between our variably aggressive cell lines and immunologic similarities between our syngeneic mouse model and human HNSCC.</p>
<p>In addition to lymphoid immune cells, cells of myeloid origin also contribute to immunomodulation in patients with HNSCC.<sup><xref ref-type="bibr" rid="bibr28-0194599812442037">28</xref></sup> Tumor cells as well as infiltrating immune cells create a cytokine milieu that can influence immature myeloid cells to display either protumor or antitumor phenotypes.<sup><xref ref-type="bibr" rid="bibr28-0194599812442037">28</xref><xref ref-type="bibr" rid="bibr29-0194599812442037"/>-<xref ref-type="bibr" rid="bibr30-0194599812442037">30</xref></sup> A heterogeneous but closely related group of immature myeloid cells in which terminal differentiation is inhibited by tumor and stromal factors are called myeloid-derived suppressor cells (MDSCs) and contribute to immune suppression in several tumor systems.<sup><xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref>,<xref ref-type="bibr" rid="bibr31-0194599812442037">31</xref></sup> In patients with HNSCC, a subset of this immature myeloid population, identified by the marker CD34<sup>+</sup>, secretes immunosuppressive cytokines, inhibits T lymphocyte function,<sup><xref ref-type="bibr" rid="bibr32-0194599812442037">32</xref>,<xref ref-type="bibr" rid="bibr33-0194599812442037">33</xref></sup> and is associated with tumor progression.<sup><xref ref-type="bibr" rid="bibr34-0194599812442037">34</xref></sup></p>
<p>In mice, MDSCs are identified by cell surface antigens Gr1<sup>+</sup> and CD11b<sup>+</sup>.<sup><xref ref-type="bibr" rid="bibr31-0194599812442037">31</xref></sup> Here, we demonstrated robust recruitment of CD11b<sup>+</sup>/Gr1<sup>+</sup> cells into the spleen and tumor microenvironment of both MOC1- and MOC2-generated tumors. Interestingly, we also demonstrated significantly elevated recruitment of CD11b<sup>+</sup>/Gr1<sup>+</sup> cells into the microenvironment of regional metastatic disease arising from MOC2-generated tumors. To our knowledge, this is the first report of recruitment of immature myeloid cells into the tumor-draining lymph node in a model of spontaneous metastasis from an epithelial tumor. Watanabe et al<sup><xref ref-type="bibr" rid="bibr35-0194599812442037">35</xref></sup> documented recruitment of CD11b<sup>+</sup>/Gr1<sup>+</sup> MDSCs into regional metastatic disease in a sarcoma model and showed that this MDSC population inhibited T lymphocyte activation independent of Tregs. Studies evaluating the presence of immature myeloid suppressor cells in deposits of regional metastasis with patients with HNSCC are lacking. Future research is needed to determine whether these immature myeloid cells are recruited into the lymph node by metastatic deposits of tumor or whether primary tumors promote a niche favorable for metastasis via cytokine-driven recruitment of immature myeloid cells into regional lymph nodes prior to regional metastasis.</p>
<p>More mature myeloid cells, such as macrophages, are present in the tumor microenvironment of patients with HNSCC as well.<sup><xref ref-type="bibr" rid="bibr36-0194599812442037">36</xref>,<xref ref-type="bibr" rid="bibr37-0194599812442037">37</xref></sup> Macrophage accumulation in HNSCC specimens is associated with advanced tumor stage at diagnosis and tumor progression.<sup><xref ref-type="bibr" rid="bibr36-0194599812442037">36</xref>,<xref ref-type="bibr" rid="bibr37-0194599812442037">37</xref></sup> Tumor-infiltrating macrophages (TAMs) can be functionally classified as antitumor (M1) and protumor (M2) variants and have been extensively studied in many cancer types.<sup><xref ref-type="bibr" rid="bibr38-0194599812442037">38</xref></sup> Differentiating M1 or M2 phenotypes based on surface marker expression profiles was not performed here. We identified that CD11b<sup>+</sup>/Gr1<sup>–</sup>/F4/80<sup>+</sup> cells, consistent with TAMs, are present in both MOC1- and MOC2-generated tumors and represent a majority of the CD11b<sup>+</sup>/Gr1<sup>–</sup> cell population. Of note, CD11b<sup>+</sup>/Gr1<sup>–</sup>/F4/80<sup>+</sup> TAMs were not present in metastatic tumor deposits arising from MOC2-generated tumors, suggesting these cells play a biologic role in primary but not metastatic disease in our model.</p>
<p>A limitation of this study, excluding the Treg depletion studies, is the lack of functional analysis reported for the immune cell types identified. Although cell surface markers suggest functional roles for each cell type identified,<sup><xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref></sup> including those for Tregs and MDSCs, verification of the roles of each cell type identified with functional analysis is necessary and is a current focus of our laboratory. In addition, our analysis excluded several immune cell types of potential importance, including gamma-delta T lymphocytes, natural killer cells, natural killer T cells, and CD4<sup>+</sup> Th17 cells, all shown to play variable roles in human HNSCC biology.<sup><xref ref-type="bibr" rid="bibr10-0194599812442037">10</xref></sup></p>
<p>The few syngeneic HNSCC models currently available have been developed artificially in vitro,<sup><xref ref-type="bibr" rid="bibr39-0194599812442037">39</xref>,<xref ref-type="bibr" rid="bibr40-0194599812442037">40</xref></sup> lack locally aggressive or metastatic potential,<sup><xref ref-type="bibr" rid="bibr39-0194599812442037">39</xref>,<xref ref-type="bibr" rid="bibr40-0194599812442037">40</xref></sup> or are of questionable cellular origin.<sup><xref ref-type="bibr" rid="bibr11-0194599812442037">11</xref>,<xref ref-type="bibr" rid="bibr41-0194599812442037">41</xref></sup> This newly established mouse model parallels carcinogen-associated human HNSCC in the mechanism of cellular transformation, intracellular signaling aberrations, aggressive growth, and metastatic potential.<sup><xref ref-type="bibr" rid="bibr13-0194599812442037">13</xref></sup> Furthermore, the malleability of the C57BL/6 mouse genetic background allows for dissection of other facets of tumor-host interactions. With the use of this syngeneic model, correlations between dysregulated intracellular signaling pathways and abrogated immune signaling and dissection of tumor–immune cell interactions within the tumor microenvironment may allow for the development of therapeutics specifically aimed at modulating both processes.</p>
<p>In summary, we have described the first comparative infiltrating immune cell analysis of 2 cell lines that display either aggressive or indolent growth phenotypes. We identified increased MHC class I expression and CD8<sup>+</sup> T-lymphocyte infiltration in tumors generated from the less aggressive cell line. In addition, we found that a significant portion of CD4<sup>+</sup> T cells infiltrating tumors generated from the more aggressive cell line were immunosuppressive FOXP3<sup>+</sup> Tregs and that antibody-mediated inhibition of these Tregs led to attenuated growth. Primary tumors generated from both cell lines, as well as regional lymph nodes containing metastatic disease from the more aggressive cell line, demonstrate robust infiltration of Cd11b<sup>+</sup>Gr1<sup>+</sup> cells. These data recapitulate the infiltrating lymphocyte profile observed in human HNSCCs and validate the utility of using this syngeneic oral cancer model to study tumor-host interactions within the tumor and metastatic microenvironment.</p>
</sec>
<sec id="section23-0194599812442037">
<title>Author Contributions</title>
<p><bold>Nancy P. Judd</bold>, performed experiments and accrued/interpreted data, authorship and approval of manuscript; <bold>Clint T. Allen</bold>, performed experiments and accrued/interpreted data, authorship and approval of manuscript; <bold>Ashley E. Winkler</bold>, performed experiments and accrued/interpreted data, critical appraisal and approval of manuscript; <bold>Ravindra Uppaluri</bold>, conceptual design, oversight of experiments and data interpretation, critical appraisal and approval of manuscript.</p>
</sec>
<sec id="section24-0194599812442037">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> Ravindra Uppaluri was supported by grants from the National Cancer Institute (K08CA090403), the American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS), and the Veterans Affairs Research Service. Nancy P. Judd was supported by NIH-T32DC00022 and the AAO/HNS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812442037">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmitz</surname><given-names>S</given-names></name>
<name><surname>Machiels</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications</article-title>. <source>Expert Rev Anticancer Ther</source>. <year>2010</year>;<volume>10</volume>:<fpage>1471</fpage>-<lpage>1484</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812442037">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hauswald</surname><given-names>H</given-names></name>
<name><surname>Simon</surname><given-names>C</given-names></name>
<name><surname>Hecht</surname><given-names>S</given-names></name>
<name><surname>Debus</surname><given-names>J</given-names></name>
<name><surname>Lindel</surname><given-names>K</given-names></name>
</person-group>. <article-title>Long-term outcome and patterns of failure in patients with advanced head and neck cancer</article-title>. <source>Radiat Oncol</source>. <year>2011</year>;<volume>6</volume>:<fpage>70</fpage>.</citation>
</ref>
<ref id="bibr3-0194599812442037">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>CT</given-names></name>
<name><surname>Lewis</surname><given-names>JS</given-names><suffix>Jr</suffix></name>
<name><surname>El-Mofty</surname><given-names>SK</given-names></name>
<name><surname>Haughey</surname><given-names>BH</given-names></name>
<name><surname>Nussenbaum</surname><given-names>B</given-names></name>
</person-group>. <article-title>Human papillomavirus and oropharynx cancer: biology, detection and clinical implications</article-title>. <source>Laryngoscope</source>. <year>2010</year>;<volume>120</volume>:<fpage>1756</fpage>-<lpage>1772</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812442037">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shankaran</surname><given-names>V</given-names></name>
<name><surname>Ikeda</surname><given-names>H</given-names></name>
<name><surname>Bruce</surname><given-names>AT</given-names></name>
<etal/>
</person-group>. <article-title>IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity</article-title>. <source>Nature</source>. <year>2001</year>;<volume>410</volume>:<fpage>1107</fpage>-<lpage>1111</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812442037">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grulich</surname><given-names>AE</given-names></name>
<name><surname>van Leeuwen</surname><given-names>MT</given-names></name>
<name><surname>Falster</surname><given-names>MO</given-names></name>
<name><surname>Vajdic</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>:<fpage>59</fpage>-<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr6-0194599812442037">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Snyderman</surname><given-names>CH</given-names></name>
<name><surname>Heo</surname><given-names>DS</given-names></name>
<name><surname>Chen</surname><given-names>K</given-names></name>
<name><surname>Whiteside</surname><given-names>TL</given-names></name>
<name><surname>Johnson</surname><given-names>JT</given-names></name>
</person-group>. <article-title>T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer</article-title>. <source>Head Neck</source>. <year>1989</year>;<volume>11</volume>:<fpage>331</fpage>-<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr7-0194599812442037">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pretscher</surname><given-names>D</given-names></name>
<name><surname>Distel</surname><given-names>LV</given-names></name>
<name><surname>Grabenbauer</surname><given-names>GG</given-names></name>
<name><surname>Wittlinger</surname><given-names>M</given-names></name>
<name><surname>Buettner</surname><given-names>M</given-names></name>
<name><surname>Niedobitek</surname><given-names>G</given-names></name>
</person-group>. <article-title>Distribution of immune cells in head and neck cancer: CD8<sup>+</sup> T-cells and CD20<sup>+</sup> B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma</article-title>. <source>BMC Cancer</source>. <year>2009</year>;<volume>9</volume>:<fpage>292</fpage>.</citation>
</ref>
<ref id="bibr8-0194599812442037">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thurlow</surname><given-names>JK</given-names></name>
<name><surname>Pena Murillo</surname><given-names>CL</given-names></name>
<name><surname>Hunter</surname><given-names>KD</given-names></name>
<etal/>
</person-group>. <article-title>Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>2881</fpage>-<lpage>2888</lpage>.</citation>
</ref>
<ref id="bibr9-0194599812442037">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uppaluri</surname><given-names>R</given-names></name>
<name><surname>Dunn</surname><given-names>GP</given-names></name>
<name><surname>Lewis</surname><given-names>JS</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers</article-title>. <source>Cancer Immun</source>. <year>2008</year>;<volume>8</volume>:<fpage>16</fpage>.</citation>
</ref>
<ref id="bibr10-0194599812442037">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>C</given-names></name>
<name><surname>Judd</surname><given-names>N</given-names></name>
<name><surname>Bui</surname><given-names>J</given-names></name>
<name><surname>Uppaluri</surname><given-names>R</given-names></name>
</person-group>. <article-title>The clinical implications of anti-tumor immunity in head and neck cancer</article-title>. <source>Laryngoscope</source>. <year>2012</year>;<volume>122</volume>:<fpage>144</fpage>-<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr11-0194599812442037">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S</given-names></name>
</person-group>. <article-title>Animal models of cancer in the head and neck region</article-title>. <source>Clin Exp Otorhinolaryngol</source>. <year>2009</year>;<volume>2</volume>:<fpage>55</fpage>-<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr12-0194599812442037">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sano</surname><given-names>D</given-names></name>
<name><surname>Myers</surname><given-names>JN</given-names></name>
</person-group>. <article-title>Xenograft models of head and neck cancers</article-title>. <source>Head Neck Oncol</source>. <year>2009</year>;<volume>1</volume>:<fpage>32</fpage>.</citation>
</ref>
<ref id="bibr13-0194599812442037">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Judd</surname><given-names>NP</given-names></name>
<name><surname>Winkler</surname><given-names>AE</given-names></name>
<name><surname>Murillo-Sauca</surname><given-names>OJ</given-names></name>
<etal/>
</person-group>. <article-title>ERK1/2 regulation of CD44 modulates oral cancer aggressiveness</article-title>. <source>Cancer Res</source>. <year>2012</year>;<volume>72</volume>:<fpage>365</fpage>-<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr14-0194599812442037">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skarnes</surname><given-names>WC</given-names></name>
<name><surname>Rosen</surname><given-names>B</given-names></name>
<name><surname>West</surname><given-names>AP</given-names></name>
<etal/>
</person-group>. <article-title>A conditional knockout resource for the genome-wide study of mouse gene function</article-title>. <source>Nature</source>. <year>2011</year>;<volume>474</volume>:<fpage>337</fpage>-<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr15-0194599812442037">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bui</surname><given-names>JD</given-names></name>
<name><surname>Uppaluri</surname><given-names>R</given-names></name>
<name><surname>Hsieh</surname><given-names>CS</given-names></name>
<name><surname>Schreiber</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins</article-title>. <source>Cancer Res</source>. <year>2006</year>;<volume>66</volume>:<fpage>7301</fpage>-<lpage>7309</lpage>.</citation>
</ref>
<ref id="bibr16-0194599812442037">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandoh</surname><given-names>N</given-names></name>
<name><surname>Ogino</surname><given-names>T</given-names></name>
<name><surname>Katayama</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis</article-title>. <source>Oncol Rep</source>. <year>2010</year>;<volume>23</volume>:<fpage>933</fpage>-<lpage>939</lpage>.</citation>
</ref>
<ref id="bibr17-0194599812442037">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ogino</surname><given-names>T</given-names></name>
<name><surname>Shigyo</surname><given-names>H</given-names></name>
<name><surname>Ishii</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker</article-title>. <source>Cancer Res</source>. <year>2006</year>;<volume>66</volume>:<fpage>9281</fpage>-<lpage>9289</lpage>.</citation>
</ref>
<ref id="bibr18-0194599812442037">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferris</surname><given-names>RL</given-names></name>
<name><surname>Whiteside</surname><given-names>TL</given-names></name>
<name><surname>Ferrone</surname><given-names>S</given-names></name>
</person-group>. <article-title>Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer</article-title>. <source>Clin Cancer Res</source>. <year>2006</year>;<volume>12</volume>:<fpage>3890</fpage>-<lpage>3895</lpage>.</citation>
</ref>
<ref id="bibr19-0194599812442037">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bergmann</surname><given-names>C</given-names></name>
<name><surname>Strauss</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease</article-title>. <source>Clin Cancer Res</source>. <year>2008</year>;<volume>14</volume>:<fpage>3706</fpage>-<lpage>3715</lpage>.</citation>
</ref>
<ref id="bibr20-0194599812442037">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chikamatsu</surname><given-names>K</given-names></name>
<name><surname>Sakakura</surname><given-names>K</given-names></name>
<name><surname>Whiteside</surname><given-names>TL</given-names></name>
<name><surname>Furuya</surname><given-names>N</given-names></name>
</person-group>. <article-title>Relationships between regulatory T cells and CD8<sup>+</sup> effector populations in patients with squamous cell carcinoma of the head and neck</article-title>. <source>Head Neck</source>. <year>2007</year>;<volume>29</volume>:<fpage>120</fpage>-<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr21-0194599812442037">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>DJ</given-names></name>
<name><surname>Koch</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Phenotypical and functional specialization of FOXP3<sup>+</sup> regulatory T cells</article-title>. <source>Nat Rev Immunol</source>. <year>2011</year>;<volume>11</volume>:<fpage>119</fpage>-<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr22-0194599812442037">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strauss</surname><given-names>L</given-names></name>
<name><surname>Bergmann</surname><given-names>C</given-names></name>
<name><surname>Gooding</surname><given-names>W</given-names></name>
<name><surname>Johnson</surname><given-names>JT</given-names></name>
<name><surname>Whiteside</surname><given-names>TL</given-names></name>
</person-group>. <article-title>The frequency and suppressor function of CD4<sup>+</sup>CD25highFoxp3<sup>+</sup> T cells in the circulation of patients with squamous cell carcinoma of the head and neck</article-title>. <source>Clin Cancer Res</source>. <year>2007</year>;<volume>13</volume>:<fpage>6301</fpage>-<lpage>6311</lpage>.</citation>
</ref>
<ref id="bibr23-0194599812442037">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strauss</surname><given-names>L</given-names></name>
<name><surname>Bergmann</surname><given-names>C</given-names></name>
<name><surname>Szczepanski</surname><given-names>M</given-names></name>
<name><surname>Gooding</surname><given-names>W</given-names></name>
<name><surname>Johnson</surname><given-names>JT</given-names></name>
<name><surname>Whiteside</surname><given-names>TL</given-names></name>
</person-group>. <article-title>A unique subset of CD4<sup>+</sup>CD25highFoxp3<sup>+</sup> T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment</article-title>. <source>Clin Cancer Res</source>. <year>2007</year>;<volume>13</volume>:<fpage>4345</fpage>-<lpage>4354</lpage>.</citation>
</ref>
<ref id="bibr24-0194599812442037">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schott</surname><given-names>AK</given-names></name>
<name><surname>Pries</surname><given-names>R</given-names></name>
<name><surname>Wollenberg</surname><given-names>B</given-names></name>
</person-group>. <article-title>Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer</article-title>. <source>Int J Mol Med</source>. <year>2010</year>;<volume>26</volume>:<fpage>67</fpage>-<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr25-0194599812442037">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Badoual</surname><given-names>C</given-names></name>
<name><surname>Hans</surname><given-names>S</given-names></name>
<name><surname>Rodriguez</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic value of tumor-infiltrating CD4<sup>+</sup> T-cell subpopulations in head and neck cancers</article-title>. <source>Clin Cancer Res</source>. <year>2006</year>;<volume>12</volume>:<fpage>465</fpage>-<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr26-0194599812442037">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prince</surname><given-names>ME</given-names></name>
<name><surname>Sivanandan</surname><given-names>R</given-names></name>
<name><surname>Kaczorowski</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>:<fpage>973</fpage>-<lpage>978</lpage>.</citation>
</ref>
<ref id="bibr27-0194599812442037">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chikamatsu</surname><given-names>K</given-names></name>
<name><surname>Takahashi</surname><given-names>G</given-names></name>
<name><surname>Sakakura</surname><given-names>K</given-names></name>
<name><surname>Ferrone</surname><given-names>S</given-names></name>
<name><surname>Masuyama</surname><given-names>K</given-names></name>
</person-group>. <article-title>Immunoregulatory properties of CD44<sup>+</sup> cancer stem-like cells in squamous cell carcinoma of the head and neck</article-title>. <source>Head Neck</source>. <year>2011</year>;<volume>33</volume>:<fpage>208</fpage>-<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr28-0194599812442037">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whiteside</surname><given-names>TL</given-names></name>
</person-group>. <article-title>The tumor microenvironment and its role in promoting tumor growth</article-title>. <source>Oncogene</source>. <year>2008</year>;<volume>27</volume>:<fpage>5904</fpage>-<lpage>5912</lpage>.</citation>
</ref>
<ref id="bibr29-0194599812442037">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pries</surname><given-names>R</given-names></name>
<name><surname>Wollenberg</surname><given-names>B</given-names></name>
</person-group>. <article-title>Cytokines in head and neck cancer</article-title>. <source>Cytokine Growth Factor Rev</source>. <year>2006</year>;<volume>17</volume>:<fpage>141</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr30-0194599812442037">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>K</given-names></name>
<name><surname>Jinhua</surname><given-names>P</given-names></name>
<name><surname>Omura</surname><given-names>K</given-names></name>
<name><surname>Azuma</surname><given-names>M</given-names></name>
</person-group>. <article-title>Multipotency of CD11b<sup>high</sup>Gr<sup>–</sup>1<sup>+</sup> immature myeloid cells accumulating in oral squamous cell carcinoma-bearing mice</article-title>. <source>Oral Oncol</source>. <year>2007</year>;<volume>43</volume>:<fpage>586</fpage>-<lpage>592</lpage>.</citation>
</ref>
<ref id="bibr31-0194599812442037">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagaraj</surname><given-names>S</given-names></name>
<name><surname>Collazo</surname><given-names>M</given-names></name>
<name><surname>Corzo</surname><given-names>CA</given-names></name>
<etal/>
</person-group>. <article-title>Regulatory myeloid suppressor cells in health and disease</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>:<fpage>7503</fpage>-<lpage>7506</lpage>.</citation>
</ref>
<ref id="bibr32-0194599812442037">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>MR</given-names></name>
</person-group>. <article-title>Protective mechanisms of head and neck squamous cell carcinomas from immune assault</article-title>. <source>Head Neck</source>. <year>2006</year>;<volume>28</volume>:<fpage>462</fpage>-<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr33-0194599812442037">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>MR</given-names></name>
<name><surname>Lathers</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers</article-title>. <source>Int J Immunopharmacol</source>. <year>1999</year>;<volume>21</volume>:<fpage>241</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr34-0194599812442037">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>MR</given-names></name>
<name><surname>Wright</surname><given-names>MA</given-names></name>
<name><surname>Lozano</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34<sup>+</sup> natural suppressor cells</article-title>. <source>Int J Cancer</source>. <year>1997</year>;<volume>74</volume>:<fpage>69</fpage>-<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr35-0194599812442037">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>S</given-names></name>
<name><surname>Deguchi</surname><given-names>K</given-names></name>
<name><surname>Zheng</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Tumor-induced CD11b<sup>+</sup>Gr<sup>–</sup>1<sup>+</sup> myeloid cells suppress T cell sensitization in tumor-draining lymph nodes</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>181</volume>:<fpage>3291</fpage>-<lpage>3300</lpage>.</citation>
</ref>
<ref id="bibr36-0194599812442037">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marcus</surname><given-names>B</given-names></name>
<name><surname>Arenberg</surname><given-names>D</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma</article-title>. <source>Cancer</source>. <year>2004</year>;<volume>101</volume>:<fpage>2779</fpage>-<lpage>2787</lpage>.</citation>
</ref>
<ref id="bibr37-0194599812442037">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rittà</surname><given-names>M</given-names></name>
<name><surname>De Andrea</surname><given-names>M</given-names></name>
<name><surname>Mondini</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression</article-title>. <source>Head Neck</source>. <year>2009</year>;<volume>31</volume>:<fpage>318</fpage>-<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr38-0194599812442037">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sica</surname><given-names>A</given-names></name>
<name><surname>Larghi</surname><given-names>P</given-names></name>
<name><surname>Mancino</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Macrophage polarization in tumour progression</article-title>. <source>Semin Cancer Biol</source>. <year>2008</year>;<volume>18</volume>:<fpage>349</fpage>-<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr39-0194599812442037">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>GR</given-names></name>
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Oechsli</surname><given-names>MN</given-names></name>
<name><surname>Hendler</surname><given-names>FJ</given-names></name>
<name><surname>Van Waes</surname><given-names>C</given-names></name>
</person-group>. <article-title>Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma</article-title>. <source>Int J Cancer</source>. <year>1999</year>;<volume>82</volume>:<fpage>377</fpage>-<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr40-0194599812442037">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoover</surname><given-names>AC</given-names></name>
<name><surname>Spanos</surname><given-names>WC</given-names></name>
<name><surname>Harris</surname><given-names>GF</given-names></name>
<name><surname>Anderson</surname><given-names>ME</given-names></name>
<name><surname>Klingelhutz</surname><given-names>AJ</given-names></name>
<name><surname>Lee</surname><given-names>JH</given-names></name>
</person-group>. <article-title>The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>2007</year>;<volume>133</volume>:<fpage>495</fpage>-<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr41-0194599812442037">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Malley</surname><given-names>BW</given-names><suffix>Jr</suffix></name>
<name><surname>Cope</surname><given-names>KA</given-names></name>
<name><surname>Johnson</surname><given-names>CS</given-names></name>
<name><surname>Schwartz</surname><given-names>MR</given-names></name>
</person-group>. <article-title>A new immunocompetent murine model for oral cancer</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>1997</year>;<volume>123</volume>:<fpage>20</fpage>-<lpage>24</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>